Institution
University of Paris
Education•Paris, France•
About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Medicine. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.
Topics: Population, Medicine, Context (language use), Transplantation, Gene
Papers published on a yearly basis
Papers
More filters
TL;DR: The atmospheric fallout of microplastics was investigated in two different urban and sub-urban sites and a rough estimation was shown showing that between 3 and 10 tons of fibers are deposited by atmospheric fallout at the scale of the Parisian agglomeration every year.
1,164 citations
TL;DR: In this paper, a different method is proposed to analyze experimental results and it is employed here to reexamine experimental data taken from the literature, and it appears that the method generally used is flawed and that it unfairly favors pseudo-second order kinetics.
1,164 citations
Technical University of Denmark1, University of Paris2, University of Washington3, Free University of Berlin4, Paris Descartes University5, Novo Nordisk Foundation6, Robert Koch Institute7, Federal Institute for Risk Assessment8, University of Antwerp9, Hvidovre Hospital10, University of Copenhagen11, Animal and Plant Health Agency12, ANSES13
TL;DR: WGS-based AST using ResFinder 4.0 provides in silico antibiograms as reliable as those obtained by phenotypic AST at least for the bacterial species/antimicrobial agents of major public health relevance considered.
Abstract: WGS-based antimicrobial susceptibility testing (AST) is as reliable as phenotypic AST for several antimicrobial/bacterial species combinations. However, routine use of WGS-based AST is hindered by the need for bioinformatics skills and knowledge of antimicrobial resistance (AMR) determinants to operate the vast majority of tools developed to date. By leveraging on ResFinder and PointFinder, two freely accessible tools that can also assist users without bioinformatics skills, we aimed at increasing their speed and providing an easily interpretable antibiogram as output.
1,155 citations
Brown University1, Harvard University2, International AIDS Society3, Stanford University4, University of British Columbia5, University of California, San Diego6, University of Alabama at Birmingham7, University of Colorado Denver8, Istituto Superiore di Sanità9, University of Paris10, University of California, San Francisco11
TL;DR: New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence.
Abstract: Objective.—To provide recommendations for antiretroviral therapy based on information
available in mid-1998.Participants.—An international panel of physicians with expertise in antiretroviral
research and care of patients with human immunodeficiency virus (HIV) infection,
first convened by the International AIDS Society–USA in December 1995.Evidence.—The panel reviewed available clinical and basic science study
results (including phase 3 controlled trials; clinical, virologic, and immunologic
end point data; data presented at research conferences; and studies of HIV
pathophysiology); opinions of panel members were also considered. Recommendations
were limited to drugs available in mid-1998.Consensus Process.—Panel members monitor new clinical research reports and interim
results. The full panel meets regularly to discuss how the new information
may change treatment recommendations. Updated recommendations are developed
through consensus of the entire panel at each stage of development.Conclusions.—Accumulating data from clinical and pathogenesis studies continue
to support early institution of potent antiretroviral therapy in patients
with HIV infection. A variety of combination regimens show potency, expanding
choices for initial regimens for individual patients. Plasma HIV RNA assays
with increased sensitivity are important in monitoring therapeutic response;
however, more data are needed to determine precisely the HIV RNA levels that
define treatment failure. Long-term adverse drug effects are beginning to
emerge, requiring ongoing attention. Some issues regarding optimal long-term
approaches to antiretroviral management are unresolved. The increased complexity
in HIV management requires ongoing monitoring of new data for optimal treatment
of HIV infection.
1,151 citations
TL;DR: In this article, the authors identified and critically reviewed the published peer-reviewed, English-language studies investigating predictive factors of fluid responsiveness in ICU patients and compared responder and nonresponder patients' characteristics before volume expansion.
1,144 citations
Authors
Showing all 102613 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Guido Kroemer | 236 | 1404 | 246571 |
| David H. Weinberg | 183 | 700 | 171424 |
| Paul M. Thompson | 183 | 2271 | 146736 |
| Chris Sander | 178 | 713 | 233287 |
| Sophie Henrot-Versille | 171 | 957 | 157040 |
| Richard H. Friend | 169 | 1182 | 140032 |
| George P. Chrousos | 169 | 1612 | 120752 |
| Mika Kivimäki | 166 | 1515 | 141468 |
| Martin Karplus | 163 | 831 | 138492 |
| William J. Sandborn | 162 | 1317 | 108564 |
| Darien Wood | 160 | 2174 | 136596 |
| Monique M.B. Breteler | 159 | 546 | 93762 |
| Paul Emery | 158 | 1314 | 121293 |
| Wolfgang Wagner | 156 | 2342 | 123391 |
| Joao Seixas | 153 | 1538 | 115070 |